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Systemic insulin sensitivity is regulated by GPS2
inhibition of AKT ubiquitination and activation in
adipose tissue
Carly T. Cederquist 1, Claudia Lentucci 1, Camila Martinez-Calejman 3, Vanessa Hayashi 1, Joseph Oroﬁno 1,
David Guertin 3, Susan K. Fried 4, Mi-Jeong Lee 2, M. Dafne Cardamone 1, Valentina Perissi 1,*
ABSTRACT
Objective: Insulin signaling plays a unique role in the regulation of energy homeostasis and the impairment of insulin action is associated with
altered lipid metabolism, obesity, and Type 2 Diabetes. The main aim of this study was to provide further insight into the regulatory mechanisms
governing the insulin signaling pathway by investigating the role of non-proteolytic ubiquitination in insulin-mediated activation of AKT.
Methods: The molecular mechanism of AKT regulation through ubiquitination is ﬁrst dissected in vitro in 3T3-L1 preadipocytes and then
validated in vivo using mice with adipo-speciﬁc deletion of GPS2, an endogenous inhibitor of Ubc13 activity (GPS2-AKO mice).
Results: Our results indicate that K63 ubiquitination is a critical component of AKT activation in the insulin signaling pathway and that counter-
regulation of this step is provided by GPS2 preventing AKT ubiquitination through inhibition of Ubc13 enzymatic activity. Removal of this negative
checkpoint, through GPS2 downregulation or genetic deletion, results in sustained activation of insulin signaling both in vitro and in vivo. As a
result, the balance between lipid accumulation and utilization is shifted toward storage in the adipose tissue and GPS2-AKO mice become obese
under normal laboratory chow diet. However, the adipose tissue of GPS2-AKO mice is not inﬂamed, the levels of circulating adiponectin are
elevated, and systemic insulin sensitivity is overall improved.
Conclusions: Our ﬁndings characterize a novel layer of regulation of the insulin signaling pathway based on non-proteolytic ubiquitination of AKT
and deﬁne GPS2 as a previously unrecognized component of the insulin signaling cascade. In accordance with this role, we have shown that GPS2
presence in adipocytes modulates systemic metabolism by restricting the activation of insulin signaling during the fasted state, whereas in absence
of GPS2, the adipose tissue is more efﬁcient at lipid storage, and obesity becomes uncoupled from inﬂammation and insulin resistance.
 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
The adipose tissue is an extremely ﬂexible organ that plays a critical
role in the regulation of energy homeostasis through both triglyceride
storage and adipokine secretion [1,2]. The health of the white adipose
tissue, and thus of the whole body, largely depends on the existence of
a proper balance between lipid storage and utilization, which is
challenged under conditions of excess food intake. Major pathological
consequences of overnutrition and obesity result from an increase in
lipid ﬂux to non-adipose organs and the development of insulin
resistance [3,4]. During the normal cycles of daily fasting and feeding,
adipose tissue metabolism is tightly regulated to respond to the en-
ergetic demands of the organism. Insulin signaling plays a key role in
this process by promoting nutrient storage during the fed state via
enhanced glucose uptake and triglyceride synthesis, and by inhibiting
triglyceride breakdown and fatty acid release through lipolysis [5,6].
The AKT/PKB kinase is an obligatory mediator of the insulin signaling
pathway downstream of phosphatidylinositol 3-kinase (PI3K) [7,8]. Full
AKT activation is promoted by dual phosphorylation by PDK1, a PI3K-
dependent kinase, and the mTOR-rictor complex. The key rate-limiting
event for AKT activation is not its phosphorylation per se, but rather its
translocation to the plasma membrane. Accordingly, full signaling
capacity is achieved by tethering AKT to the plasma membrane [9e
12]. Intriguingly, recent evidence indicates that AKT recruitment to
the membrane, and thus activation, upon stimulation with the growth
factors EGF and IGF is unexpectedly regulated through K63 ubiquiti-
nation [13e15]. However, it is currently unknown whether AKT
ubiquitination similarly contributes to the regulation of metabolic ho-
meostasis through modulation of insulin signaling.
Ubiquitination is a reversible modiﬁcation that is achieved via the
sequential actions of several classes of enzymes, including an ubiquitin
(Ub)-activating enzyme (E1), an Ub-conjugating enzyme (E2), and an
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Ub ligase (E3) [16,17]. Poly-ubiquitination of target proteins with
chains of different topology can promote either protein degradation or
serve, as in the case of other post-translational modiﬁcations, to in-
ﬂuence protein function and interactions [18,19]. The key E2 enzyme
for promoting the formation of non-proteolytic K63 ubiquitin chains is
Ubc13, which catalyzes the synthesis of ubiquitin chains in complex
with the non-catalytic subunits Mms2/Uev1A and speciﬁc E3 ligases
[20e22]. Consistent with the ﬂexibility of ubiquitination as a tight
regulatory switch for signaling pathways is the existence of multiple
strategies to rapidly reverse the active mark. Among them, and best
characterized, is the removal of ubiquitin modiﬁcations by chain
speciﬁc deubiquitinases [16,23e25], as reported in the case of AKT
deubiquitination by CYLD [26,27]. However, an equally if not more
effective strategy, is restricting the deposition of the ubiquitin chains
through inhibition of the ubiquitination machinery. Examples of in-
hibitors behaving in this manner are the ubiquitin thioesterase OTUB1
in the DNA damage response pathway and G-Protein Suppressor 2
(GPS2) in the TNFR1 signaling pathway [28,29].
GPS2 is a small multifunctional protein that was originally identiﬁed
while screening for suppressors of Ras activation in the yeast phero-
mone response pathway [30]. Recent studies by our lab and others
indicate that GPS2 plays an important anti-inﬂammatory role in adi-
pose tissue and macrophages and is required for the expression of
genes regulating cholesterol and triglyceride metabolism [29,31e34].
Due to multiple functional interactions existing between GPS2 and
various transcriptional regulators, GPS2 activity has been studied
mainly in the context of its nuclear functions, including both tran-
scriptional repression and activation [29,31,32,34e42]. However,
GPS2 also plays an important non-transcriptional role in the cytosol by
regulating JNK activation downstream of TNFR1 [29]. Intriguingly, our
ﬁndings reveal that GPS2 activity in different cellular compartments
relies on a conserved regulatory strategy based on the inhibition of
ubiquitin conjugating complexes that are responsible for the formation
of K63 ubiquitin chains (TRAF2/Ubc13 in the cytosol and RNF8/Ubc13
in the nucleus) [29,34]. Furthermore, recent data indicate that GPS2
directly inhibits Ubc13 enzymatic activity (Unpublished data; Lentucci
et al., under revision), suggesting that GPS2-mediated regulation might
extend to other signaling pathways relying on Ubc13-mediated ubiq-
uitination events. Here, we have investigated the hypothesis that GPS2
is required for restricting the activation of the insulin signaling pathway
through inhibition of Ubc13-mediated ubiquitination of AKT.
2. EXPERIMENTAL PROCEDURES
2.1. Animals studies
Fat-speciﬁc GPS2 knockout mice (GPS2-AKO) were generated using a
cre/lox approach and maintained on a mixed 129sv/C57BL6J back-
ground. Conditional GPS2 ﬂoxed mice were generated by inGenious
Targeting Laboratory. The 9.52 kb region used to construct the tar-
geting vector was ﬁrst sub cloned from a positively identiﬁed C57BL/6
(RP23: 91G16) BAC clone into a w2.4 kb backbone vector (pSP72,
Promega) containing an ampicillin selection cassette. The total size of
the targeting construct (including vector backbone and Neo cassette) is
w13.62 kb. The region was designed such that the short homology
arm (SA) extends about 2.55 kb 30 to exon 6. The long homology arm
(LA) ends 50 to exon 3 and is 6.07 kb long. A pGK-gb2 loxP/FRT Neo
cassette is inserted on the 30 side of exon 6 and the single loxP site is
inserted 50 of exon 3. The target region is 0.90 kb and includes exon
3e6. The targeting vector was linearized by NotI and then transfected
by electroporation of BA1 (C57BL/6129/SvEv) hybrid embryonic stem
cells. After selection with G418 antibiotic, surviving clones were
expanded for PCR analysis to identify recombinant ES clones and
control for retention of the third LoxP site. Secondary conﬁrmation of
positive clones was performed by Southern Blotting analysis prior to
microinjection into C57BL/6 blastocysts. Resulting chimeras with a
high percentage agouti coat color were mated to wild-type C57BL/6J
mice to generate F1 heterozygous offspring. The Neo cassette was
excised by crossing with FLP mice (Jackson Laboratories). Adipose
tissue speciﬁc deletion was achieved by crossing Gps2ﬂox/ﬂox mice with
heterozygous Adipoq-Cre C57BL/6J transgenic mice expressing Cre
recombinase under control of the adiponectin promoter [43]. Male
mice and littermate controls were used for all experiments. Mice were
maintained on standard laboratory chow diet in a temperature
controlled facility on a 12-hour light/dark cycle. All animal studies were
approved by the Boston University Institutional Animal Care and Use
Committee (IACUC) and performed in strict accordance of NIH guide-
lines for animal care.
2.2. Body composition analysis and metabolic testing
Mice body composition was assessed by non-invasive MRI scanning
on an EchoMRI 700 (BUSM Metabolic Phenotyping core). Glucose
Tolerance Test (GTT) and Insulin Tolerance Test (ITT) were performed
according to established protocols [44]. Brieﬂy, mice were starved
overnight or 4e6 h for GTT and ITT, respectively. Blood glucose levels
were measured, at the described time points after glucose (1.5 mg/g
body weight) or insulin (Humulin R, Lilly) (0.5 U/kg body weight) IP
injection, from tail nicking using a OneTouch Ultra glucometer. Plasma
was collected from overnight fasted mice after cardiac puncture and
proﬁled using Milliplex Multiplex Assays (Millipore, BUSM Analytical
Core) and Free Fatty Acid Fluorometric Assay (Cayman Chemical).
2.3. H&E staining
Upon harvesting, adipose tissue depots and liver tissues were incu-
bated at 4 C in Z-ﬁx solution (Anatech LTD) overnight. Tissues were
then transferred to 70% ethanol, parafﬁn embedded, sectioned, and
stained with hematoxylin and eosin (Tuft Pathology Core/BNORC Adi-
pose Biology Core). Imaging of adipocyte cell size was performed as
described [45,46].
2.4. Cell culture and isolation
3T3-L1 preadipocytes (American Type Culture Collection) were
cultured in high glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% fetal calf serum (Hyclone) under 5% CO2. Cells were
transfected using Lipofectamine 2000 (Invitrogen) and Opti-MEM
reduced serum media (Thermo Fisher Scientiﬁc) according to each
manufacturer’s instructions. Cells were serum starved overnight prior
to 100 nM insulin (Life Technologies) treatment for described time
points. The following siRNAs were used: MISSION siRNA universal
negative control (Sigma), siGPS2 (#s80309, 20 nM, Ambion), siUBC13
(#s123784, 20 nM, Ambion).
For in vitro differentiated adipocytes, the stromal vascular fraction
(SVF) was isolated from adipose tissue depots after collagenase type I/
dispase II digestion in 4% BSA KRH buffer for 45 min then washed,
ﬁltered, and spun down at 900 rpm for 10 min. Cells were cultured in
high glucose DMEM with 10% fetal bovine serum (Hyclone) and 1
pen/strep until conﬂuence. Two days later, in vitro adipogenic differ-
entiation was induced using a standard insulin, IBMX (Sigma), and DEX
(Sigma) cocktail for 2 days then changed to maintenance media
containing high glucose DMEM with 10% fetal bovine serum, pen/
strep, and insulin for 12 additional days.
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Primary mature adipocytes were isolated from adipose tissue depots
using collagenase type I/dispase II (Fisher) digestion in 4% BSA
(Sigma) Kreb-Ringer HEPES (KRH) buffer for 45 min, then ﬁltered and
separated by ﬂoating and washed 3 times in 1% BSA KRH buffer prior
to resuspension in lysis buffer for protein extraction or Trizol for RNA
analysis.
Akt null cells are UBC-Cre ERT2; AKT1 ﬂ/ﬂ, AKT2 ﬂ/ﬂ in an AKT3 KO
background. To generate this line, primary brown adipocyte precursors
(bAPC) cells were isolated from P1 neonates and immortalized with
pBabe-SV40 Large T antigen. To induce AKT1 and AKT2 deletion UBC-
Cre ERT2; AKT1 ﬂ/ﬂ, AKT2 ﬂ/ﬂ cells were treated on 2 consecutive
days with 1 mM 4-hydroxy tamoxifen and on the 3rd day the media was
changed to regular media to allow protein turnover. On the 4th day,
cells were plated during the morning at 80% conﬂuence, serum
removed later in the day for overnight starvation prior to 150 insulin
treatment (150 nM) and protein extraction.
2.5. Protein isolation, western blot analysis and
immunoprecipitation
Whole cell extracts were prepared from cultured cells or mouse tissue
by homogenization in lysis buffer (50 mM Tris HCl pH 8, 250 mM NaCl,
5 mM EDTA, 0.5% NP-40) supplemented with 0.1 mM PMSF, 10 mM
NEM (Thermo ﬁsher scientiﬁc), 1 protease inhibitors (Pierce), and
1 phosphatase inhibitors (Pierce). Protein concentrations were
analyzed using the Bradford assay (Biorad) and normalized for protein
loading. Immunoprecipitation was performed on whole cell lysates
upon incubation of indicated antibodies overnight followed by collec-
tion of immune complexes with Protein A-sepharose 4B conjugate
(Thermo ﬁsher scientiﬁc), SDS-PAGE electrophoresis, and western
blotting as previously described [29]. The following antibodies were
used for western blotting: Anti-GPS2-N antibody was generated in
rabbit against a speciﬁc peptide representing aa 1e11, B-Tubulin
(T4026, 1:2000, Sigma), Phospho-HSL ser563 (#4139, 1:1000, Cell
Signaling), HSL (#4107S, 1:1000, Cell Signaling), Phospho-PKA R2
ser99 (#ab32390, 1:1000, Abcam), PKA R2 (#ab38949, 1:1000,
Abcam), Phospho-(ser/thr) PKA substrates (#9621, 1:1000, Cell
Signaling), Phospho-AKT ser473 (#9271, 1:500, Cell Signaling),
Phospho-AKT thr308 (#9275, 1:500, Cell Signaling), AKT (#9272,
1:1000, Cell Signaling), Phospho-GSK3B ser9 (#9322, 1:1000, Cell
Signaling), GSK3B (#9315, 1:1000, Cell Signaling), Phospho-ACC
ser79 (#3661, 1:1000, Cell Signaling), ACC (#3676, 1:1000, Cell
Signaling), Phospho-AMPK thr172 (#2535, 1:1000, Cell Signaling),
AMPK (#2603, 1:1000, Cell Signaling), Polyubiquitin K63-linkage-
speciﬁc (HWA4C4, 1:500, Enzo Lifescience), AKT1 (1:1000, Cell
Signaling), AKT2 (1:1000, Cell Signaling), S6 (1:1000, Cell Signaling),
Phospho-S6 (1:1000, Cell Signaling), HA (1:1000, Cell Signaling),
Phospho-JNK thr183/tyr185 (#4668, 1:1000, Cell Signaling), JNK
(#sc-571, 1:1000, Santa Cruz).
2.6. RNA isolation and gene expression analysis
Total RNA extracted from cultured cells, primary adipocytes, or mouse
tissue was puriﬁed using RNeasy plus mini columns (Qiagen) and
reverse transcribed using the iScript cDNA Synthesis System (Biorad)
according to manufacturers’ instructions. PCR reactions were per-
formed using Fast Sybr Master Mix (ABI) on a ViiA7 Real-Time PCR
System. Relative mRNA expression was determined after normalization
to the housekeeping gene, cyclophilin A. Data are shown as
mean  SEM between the indicated n value. Statistical signiﬁcance
was calculated by two-tailed Student’s t test; *represents p
value< 0.05 and **p value< 0.01. All primer sequences are available
upon request.
2.7. FACS analysis
SVF cells were puriﬁed as described above. Flow cytometry analyses
were performed using the following anti-mouse antibodies: PerCP anti
CD11b (Biolegend), FITC antiF4/80 (BioRAD). Single cell suspensions
were stained with Aqua Zombie dye, washed, pre-blocked with mouse
FcBlock (Biolegend), and stained with antibody cocktails in the presence
of Brilliant Violet buffer (BD Biosciences). Ultracomp beads (eBioscience)
stained with abovementioned antibodies and ArC beads (Life Technol-
ogies) stained with Aqua Zombie dye were used for compensation in
FACSDIVA. All data were acquired on a SORP LSRII (BD Biosciences). At
least 20,000 events were collected from each sample. Manual data
analysis was performed by a blinded investigator using FlowJo 10.
Results presented are from three independent experiments, with sta-
tistical signiﬁcance calculate by two-tailed Student’s t test.
2.8. Lipolysis assay
In vitro differentiated cells were washed with PBS then incubated with
high glucose DMEMþ 2% BSA without serum for 2e3 h, then washed
with phenol-free DMEM without serum and incubated in serum free
phenol free DMEM þ 2% BSA with or without 10 mM isoproterenol
(Sigma) for 1 h. Media was collected for measuring the released
glycerol using the free glycerol reagent (Sigma). Glycerol concentra-
tions were calculated from a standard curve and values normalized to
protein concentration per well assessed by Bradford assay as
described above. Results shown include data points from three inde-
pendent experiments, each time the assay was performed with
technical triplicates.
3. RESULTS
3.1. AKT activation in the insulin signaling cascade is regulated by
ubiquitination
Non-proteolytic ubiquitination of AKT has been recently described as a
key step in the activation cascades downstream of EGF and IGF receptor
stimulation [13,47]. Despite some differences in the enzymatic ma-
chineries that are enlisted in the two different pathways, in both cases,
K63 ubiquitination plays a critical role in promoting AKT recruitment to
the plasma membrane [13,47]. Membrane recruitment of AKT through
anchoring to phosphoinositol-3,4,5-triphosphate (PIP3) is also a limiting
step in the insulin signaling pathway [48,49]. However, it is currently
unknown whether ubiquitination is required for the activation of AKT
upon insulin stimulation. To address this question, we ﬁrst asked
whether AKT is post-translationally modiﬁed by the addition of K63
ubiquitin chains upon insulin stimulation of 3T3-L1 preadipocytes. As
shown in Figure 1A, we observed that AKT undergoes K63 ubiquiti-
nation within minutes of insulin stimulation. The peak of ubiquitination
slightly precedes AKT maximal phosphorylation by the
phosphoinositide-dependent protein kinase 1 (PDK1) (Figure 1A), in
accord with the proposed function. Next, we addressed whether
ubiquitination occurs on the same sites described in the context of EGF/
IGF signaling [13], and whether this modiﬁcation is required for acti-
vation of the insulin signaling pathway. To answer these questions, we
reconstituted AKT1/2/3 null cells, generated from primary brown
adipocyte precursors, with either wild type HA-AKT2 or HA-AKT2 mu-
tants in which we had disrupted either Lys8 (AKT2-K8R), Lys14 (AKT2-
K14R), or both (AKT2-K8R/K14R) by targeted mutagenesis. Their
overexpression in AKT null cells revealed that the single mutants were
still partially phosphorylated upon insulin stimulation, whereas removal
of both ubiquitination sites resulted in a complete loss of AKT phos-
phorylation (Figure 1B). The activation of downstream AKT targets, such
as PRAS40 and ribosomal protein S6, was also inhibited in cells
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reconstituted with the double mutant (Figure 1B). Together, these re-
sults indicate that AKT ubiquitination is a required step for full activation
of the insulin signaling pathway. To further conﬁrm this conclusion and
explore which ubiquitination machinery mediates AKT ubiquitination
within the insulin pathway, we downregulated Ubc13, the E2 conju-
gating enzyme responsible for the synthesis of K63 ubiquitin chains, by
transient siRNA transfection. Ubc13, in concert with speciﬁc E3 ligases,
was previously found responsible for mediating the ubiquitination, and
thus activation, of AKT upon stimulation of IGF, EGF and ErbB receptors
[13,47,50]. In accord with these results, we observed that basal acti-
vation of AKT, albeit already very low, is reduced upon Ubc13 down-
regulation. In addition, our results indicate that disrupting AKT
ubiquitination through downregulation of Ubc13 signiﬁcantly impaired
insulin-dependent phosphorylation of AKT (Figure 1C and Supplemental
Figure S1A). Together, our data indicate that AKT is ubiquitinated upon
insulin stimulation and that Ubc13-mediated K63 ubiquitination is
required for full activation of AKT and its downstream targets, hence
raising the interesting question of whether AKT ubiquitination can be
modulated to regulate insulin signaling.
Previous studies from our lab show that GPS2 negatively regulates
different cellular functions through inhibition of K63 ubiquitination
events [29,34]. Recent work has revealed that this effect is achieved
through direct inhibition of Ubc13 enzymatic activity (Unpublished data;
Lentucci et al., under revision). Because our data indicate that Ubc13-
mediated ubiquitination is required for AKT phosphorylation and acti-
vation, we then asked whether GPS2 negatively regulated the acti-
vation of the insulin pathway. To investigate this hypothesis, we
monitored AKT activation in 3T3-L1 preadipocytes upon modulation of
GPS2 expression. First, we downregulated GPS2 by transient siRNA
transfection in 3T3-L1 preadipocytes (GPS2-KD) (Supplemental
Figure S1B). A signiﬁcant increase in the basal level of AKT phos-
phorylation was observed upon GPS2 downregulation (Figure 1D),
indicating that GPS2 is required for restricting the constitutive acti-
vation of AKT in proliferating cells under basal conditions. Similar re-
sults were observed in human 293T cells (Figure 1E), suggesting that
GPS2-mediated regulation of AKT is conserved among different cell
types. Next, to speciﬁcally investigate the relevance of GPS2-mediated
inhibition in the context of insulin signaling, we starved GPS2 KD cells
and subjected them to insulin stimulation. Again, AKT activation was
enhanced in GPS2-KD cells (Figure 1F).
Together, these results reveal that Ubc13-mediated K63 ubiquitination
of AKT represents a novel, key regulatory node of the insulin signaling
Figure 1: AKT ubiquitination and activation upon insulin stimulation is regulated by the opposing actions of the ubiquitin conjugating enzyme Ubc13 and its inhibitor GPS2. (A)
Detection of K63 ubiquitination by IP/WB of AKT in 3T3-L1 preadipocytes serum starved overnight prior to stimulation with 100 nM insulin. Phosphorylation of AKT on Thr308 is
measured in parallel on whole cell extracts from the same cells and normalized to total AKT levels. (B) Inducible AKT1 and AKT2 deletion upon 4-hydroxy tamoxifen treatment (4OH-
Tam) is rescued by transient overexpression of AKT2 WT or ubiquitination mutants. Protein expression levels and insulin mediated activation of AKT2 and downstream effectors
PRAS40 and ribosomal protein S6 are assayed by WB in whole cell extracts. (C) WB analysis of phospho-AKT/total AKT on whole cell extracts from siCTRL versus siUBC13
transiently transfected 3T3-L1 preadipocytes. Cells were stimulated with insulin (50) after overnight serum starvation. (D) WB analysis of phospho-AKT/total AKT and phospho-
GSK3B/total GSK3B in cytosolic cell extracts from proliferating 3T3-L1 preadipocytes transiently transfected with siCTRL (WT) or siGPS2 (GPS2-KD). (E) WB analysis of
phospho-AKT/total AKT in whole cell extracts from 293T cells. (F) WB analysis of phospho-AKT/total AKT in whole cell extracts from WT and GPS2-KD 3T3-L1 preadipocytes starved
overnight prior to insulin stimulation (30). All western blots are representative images of at least three independent experiments.
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cascade. GPS2, by virtue of its ability to inhibit Ubc13 enzymatic ac-
tivity, emerges as a novel regulator of the insulin signaling pathway
required for restricting the activation of AKT and downstream effectors
both in presence and absence of stimulation.
3.2. Constitutive AKT ubiquitination and activation in GPS2-
deﬁcient adipocytes
Properly functioning insulin signaling is especially important in adipo-
cytes to maintain cell homeostasis and allow for appropriate responses
to metabolic cues. Based on our ﬁndings of GPS2 acting as a negative
regulator of AKT activation, we hypothesized that GPS2 would play an
important physiologic role in adipose tissue. To investigate the physi-
ologic relevance of GPS2 in regulating insulin signaling in the adipose
tissue, we generated an adipo-speciﬁc knockout mouse model (GPS2-
AKO) by crossing GPS2ﬂ/ﬂ mice, carrying LoxP sites ﬂanking exons 3e6,
with Adipo-Cre mice (Jackson laboratories) [43]. The efﬁciency of this
deletion strategy was conﬁrmed by genomic PCR, western blotting, and
gene expression analysis (Figure 2AeD). Together, these experiments
conﬁrmed that GPS2 deletion is speciﬁc to mature adipocytes within the
adipose tissue. Then, we investigated in in vitro differentiated adipo-
cytes from the stromal vascular fraction (SVF) of either wild type (WT) or
mutant (GPS2-AKO) mice the hypothesis that loss of GPS2 results in
increased ubiquitination and activation of AKT. The efﬁciency of dif-
ferentiation was similar for cells of both genotypes (Supplemental
Figure S2). However, when assaying the level of AKT ubiquitination
by IP/WB using an antibody speciﬁc against K63 ubiquitin chains for
detection, we found a striking increase in AKT-associated ubiquitin
chains in GPS2-deﬁcient adipocytes compared to their wildtype coun-
terparts (Figure 2E). The increase in ubiquitination was associated with
enhanced basal phosphorylation on Ser473 and Thr308 both in absence
of stimulation and upon short-term insulin treatment (Figure 2F), con-
ﬁrming that AKT ubiquitination and activation are strongly enhanced in
cultured adipocytes depleted of GPS2.
Next, we conﬁrmed that insulin-dependent stimulation of AKT is
affected by GPS2 deletion in vivo by monitoring AKT activation in ad-
ipose tissue under fasted and insulin stimulated conditions. Strikingly,
we observed a signiﬁcant increase in basal phosphorylation of AKT in
both the whole subcutaneous adipose tissue depot and in mature
adipocytes isolated from the epididymal adipose tissue depot of GPS2-
AKO mice following overnight fasting (Figure 2G). In the same condi-
tions, removal of GPS2-mediated inhibition of Ubc13 activity in adi-
pocytes also led to increased activation of JNK (Figure 2H), as expected
Figure 2: Sustained AKT activation in Adipo-speciﬁc GPS2 Knockout (GPS2-AKO) mice. (A) Conﬁrmation of GPS2 deletion in the adipose tissue of GPS2-AKO mice by genomic DNA
analysis. (B) RT-qPCR analysis of GPS2 mRNA expression in white epididymal (EPI), subcutaneous (SC), and brown (BAT) adipose tissue depots and liver (LIV) from AKO versus WT
mice, n ¼ 6e7. (C) GPS2 mRNA expression in primary adipocytes isolated from white fat depots, n ¼ 3e4. (D) Conﬁrmation of protein knockout by WB in extracts from WAT, BAT,
and LIV tissues. (E) IP/WB analysis of AKT ubiquitination with K63 ubiquitin chains in in vitro differentiated adipocytes from AKO versus WT mice. (F) WB analysis of phospho-AKT/
AKT in whole cell extracts from in vitro differentiated adipocytes upon insulin stimulation (3’) after overnight serum starvation. (G) WB analysis of phospho-AKT/total AKT on whole
cell extracts from WAT tissue and primary adipocytes isolated from the EPI tissue after overnight fast. (H) WB analysis of phospho-JNK/total JNK on whole cell extracts from primary
adipocytes. (I) WB analysis of phospho-AKT/total AKT and phospho-GSK3B/total GSK3B in whole cell extracts from WAT after i.p. insulin injection (0.5 U/kg body weight). Results
are expressed as mean H SEM. Statistical signiﬁcance was calculated by two-tailed Student’s t test; * represents p value < 0.05 and **p value < 0.01. All western blots are
representative images of at least three independent experiments.
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based on previous ﬁndings [29,39]. In addition, we observed a sig-
niﬁcant increase in the level of AKT phosphorylation and activation in
the subcutaneous adipose tissue when mice were injected with insulin
for a short time prior to sacriﬁce (Figure 2I). Enhanced activation of
insulin signaling pathways downstream of AKT in the adipose tissue
from GPS2-AKO mice was conﬁrmed by augmented phosphorylation of
AKT target substrate GSK3b (Figure 2I). Therefore, together, our re-
sults indicate that GPS2 deletion promotes sustained basal and insulin-
stimulated phosphorylation and activation of AKT, and downstream
effectors of the insulin signaling pathway, in vivo in the adipose tissue.
3.3. Altered regulation of lipolysis and lipogenesis in GPS2-AKO
mice causes adipocyte hypertrophy and excessive body adiposity
A tight regulation of insulin action in adipose tissue is required for the
proper modulation of nutrient storage and mobilization throughout the
daily cycles of fasting and feeding [7,51,52]. Our in vitro and in vivo
results combined suggest that removal of GPS2-mediated regulation is
sufﬁcient to promote aberrant activation of the insulin signaling
pathway through constitutive phosphorylation and activation of AKT.
Thus, we asked whether the fat-speciﬁc deletion of GPS2 affects
nutrient storage, lipid ﬂuxes and whole body metabolism in vivo. First,
Figure 3: Increased body weight, fat mass, and adipocyte cell size in GPS2-AKO mice. (A) Representative image of whole body morphology of adult WT and GPS2-AKO mice. (B)
Progressive body weight gain in AKO versus WT mice, WT n ¼ 5e9, KO n ¼ 7e11. (C) Total body weight of 4e6 months old mice, n ¼ 5. (D) Body composition analysis of total fat
versus lean mass measured by EchoMRI scanning of WT and AKO mice at 4e6 months old, n ¼ 5. (E) Representative images of gross appearance of EPI, SC, and BAT depots in
AKO versus WT mice at 4e6 months old. (F) Individual adipose tissue depot and liver weights in AKO versus WT mice at 4e6 months old, n ¼ 9e11. (G) Representative H&E
staining of parafﬁn-embedded EPI and SC sections imaged at 10 magniﬁcation. Results are expressed as mean H SEM. Statistical signiﬁcance was calculated by two-tailed
Student’s t test; *represents p value < 0.05 and **p value < 0.01.
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we observed that GPS2-AKO mice were healthy and fertile but could be
easily distinguished from their wild type (WT) littermates based on their
larger size (Figure 3A). The difference in body weight was not apparent
at birth but increased gradually with time (Figure 3B) and became
signiﬁcant once mice reached adulthood (Figure 3C). Echo-MRI scans
of these mice conﬁrmed that the increase in body mass was attributed
to an increase in fat mass, without signiﬁcant changes in lean mass
(Figure 3D). Gross appearance revealed that all adipose tissue depots
appeared larger when comparing GPS2-AKO to WT littermates
(Figure 3E). Weights of individual white fat depots were signiﬁcantly
higher for GPS2-AKO mice (Figure 3F). The interscapular brown
adipose tissue (BAT) also trended to be larger (Figure 3F). The
enhanced adiposity correlated with a substantial increase in the size of
adipocytes (hypertrophy) within both the SC and EPI depots (Figure 3G).
In conclusion, these data indicate that GPS2-depleted adipocytes
expand more than their wild type counterparts, resulting in elevated
adipose tissue mass and larger body weight, even when mice are fed a
normal chow diet.
Adipocytes are the primary site of energy storage. The balance be-
tween lipid storage in the form of triglycerides and mobilization as
released free fatty acids is directly regulated by insulin through AKT-
dependent as well as AKT-independent pathways [4,53,54] In this
Figure 4: Improved lipid storage in the white adipose tissue of GPS2-AKO mice as a result of impaired lipolysis and increased lipogenesis. (A) WB analysis of phospho-HSL/total
HSL in whole cell extracts of primary adipocytes isolated from the EPI adipose tissue depot of AKO versus WT mice after overnight fasting. (B) WB analysis of phospho-HSL/total
HSL protein levels in whole cell extracts from in vitro differentiated adipocytes in fasted or isoproterenol (10 mM) stimulated conditions. (C) WB analysis for markers of active
lipolysis in whole cell extracts from the WAT of fasted mice. (D) Basal and isoproterenol induced lipolysis assay on in vitro differentiated adipocytes. Statistical signiﬁcance was
calculated comparing 3 independent experiments. (E) Percentage of total body weight loss after prolonged overnight fast, n ¼ 7. (F) qPCR analysis of lipogenic markers in WAT of
AKO versus WT mice, n ¼ 5e7. (G) WB analysis of phospho-ACC/total ACC and phospho-AMPK/total AMPK in whole cell extracts from the WAT of fasted mice. Results are
expressed as mean H SEM. Statistical signiﬁcance was calculated by two-tailed Student’s t test; *represents p value < 0.05 and **p value < 0.01. All western blots are
representative images of at least three independent experiments.
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context, a major physiological function of insulin in the postprandial,
anabolic state is to support the accumulation of lipid storage by pro-
moting de novo lipogenesis while restraining lipid mobilization via
lipolysis. Based on the enhanced AKT activation we observed in the
adipose tissue of both fasted and insulin-stimulated GPS2-AKO mice,
we asked whether an impairment of the regulated cycles of lipogenesis
and lipolysis was underlying the increased adipocyte cell size and body
adiposity of these mice.
Our previous work showed that GPS2 overexpression in aP2-GPS2
transgenic mice promoted a strong increase in the phosphorylation,
and thus activation, of hormone sensitive lipase, HSL [34]. Here, we
found that GPS2 deletion promoted the opposite phenotype. In isolated
adipocytes from fasted GPS2-AKO mice, HSL phosphorylation was
completely blunted, in contrast to the strong signal observed in adi-
pocytes from WT littermates (Figure 4A). Similar results were observed
upon isoproterenol stimulation of in vitro differentiated adipocytes from
WT or GPS2-AKO mice, with the induced HSL phosphorylation being
severely reduced in absence of GPS2 (Figure 4B). In agreement with
GPS2 being required for the priming of HSL and ATGL promoters only
during the early stages of adipocyte differentiation prior to the
expression of adiponectin [34], we did not observe any signiﬁcant
change in the expression of HSL upon GPS2 deletion in adiponectin-
expressing, mature adipocytes. However, we unexpectedly observed
a trend for increased ATGL mRNA and protein levels, which could
reﬂect an attempt at compensating for the reduced lipolysis (Figure 4B
and Supplement Figure S2A and S2B). Upstream regulation of the
lipolysis pathway was also impaired, as shown by reduced phos-
phorylation of PKA and PKA substrates in subcutaneous white adipose
tissue homogenates (Figure 4C). To further conﬁrm that lipid mobili-
zation from the adipose tissue is impaired in GPS2-AKO mice, we
conﬁrmed that lipolysis is impaired in absence of GPS2 ex vivo and
in vivo. Ex vivo, the rate of lipolysis, as assessed by measuring glycerol
release from in vitro differentiated adipocytes, was severely reduced in
GPS2-deﬁcient cells compared to wild type counterparts (Figure 4D).
In vivo, GPS2-AKO mice lost signiﬁcantly less body weight after an
overnight fast than their WT littermates, in accordance with their
impaired ability to promote lipid release from triglyceride stores
(Figure 4E). Thus, our current and previous work combined indicates
that GPS2 is indeed required for lipid mobilization through lipolysis.
Interestingly, it appears that GPS2 plays complementary genomic and
non-genomic roles in regulating different steps of the lipolysis pathway
in differentiating preadipocytes and mature adipocytes.
Next, we investigated the effect of enhanced insulin signaling on the
regulation of lipogenesis. In both adipose tissue and liver, acute
stimulation of de novo lipogenesis (DNL) is mainly regulated by insulin
and glucose availability through the transcriptional activities of
SREBP1, ChREBP and LXRs [5,55e57]. Gene expression analysis by
RT-qPCR showed a signiﬁcant increase in the mRNA levels of the
lipogenic genes Fasn, Dgat1, Dgat2, AGPAT2, and Acaca in the sub-
cutaneous WAT of GPS2-AKO mice compared to WT littermates
(Figure 4F). In addition to the transcriptional regulation of enzyme
availability, insulin-mediated activation of AKT impinges upon DNL
through AMPK inhibition, resulting in dephosphorylation and activation
of the Acetyl-CoA carboxylase (ACC) [58]. In agreement with AKT being
constitutively activated in GPS2-AKO mice, we observed both a sig-
niﬁcant decrease in active AMPK and decreased phosphorylation of
ACC in the white adipose tissue of GPS2-AKO mice (Figure 4G).
Together, these results are consistent with the hypothesis that both in
the fed and fasted state, lipogenesis is enhanced while lipid mobili-
zation is impaired in GPS2-AKO mice, markedly shifting the balance
toward fat storage.
3.4. Fat-speciﬁc deletion of GPS2 results in improved systemic
insulin sensitivity
Sustained insulin signaling, improved lipid storing capacity of the
adipose tissue, impaired adipose tissue lipolysis and enhanced DNL
have all been associated with improved systemic insulin sensitivity
[51,59e62], suggesting that adipo-speciﬁc GPS2 deletion might be
beneﬁcial for the organism. However, obesity is generally associated
with chronic inﬂammation and with the development of insulin resis-
tance [63e65]. To investigate how the removal of GPS2 and the
corresponding enhanced insulin signaling in the adipose tissue affect
the maintenance of systemic homeostasis, we ﬁrst assessed the level
of local inﬂammation in the adipose tissue by RT-qPCR and FACS
analysis. Surprisingly, given GPS2 previously reported anti-
inﬂammatory role and the obesity that characterize GPS2-AKO mice,
no signiﬁcant differences were observed in either the expression of
gene markers of inﬂammation or in the amount of macrophages
present within the adipose tissue (Figure 5A and B).
Next, we sampled plasma from fasted WT and GPS2-AKO littermates
for the presence of secreted adipokines. Plasma levels of the anti-
inﬂammatory and insulin-sensitizing hormone adiponectin [66,67]
were found to be signiﬁcantly elevated in GPS2-AKO mice despite
the reported increase in body adiposity (Figure 5C), whereas no sig-
niﬁcant differences were observed in the amount of circulating leptin
(Figure 5C). Consistent with an increase in circulating adiponectin and
with adiponectin playing an important role in promoting the “healthy
expansion” of the adipose tissue [68,69], we did not observe any
evidence of hepatic steatosis in the liver of GPS2-AKO mice despite
their increase in total body fat (Figure 5D). Accordingly, the expression
of both ChREBP and SREBP1c, key markers of DNL, were found
downregulated in the liver of GPS2-AKO mice (Figure 5E). The
expression of key gluconeogenic enzymes, such as G6Pase, FBP1, and
PEPCK was also reduced in the liver of GPS2-deﬁcient mice
(Figure 5E). Furthermore, we sampled circulating free fatty acids (FFA)
from GPS2-AKO and WT littermates and found a slight trend to
decrease but no signiﬁcant differences. While this result could initially
appear surprising in the face of the decreased lipolysis, it has to be
taken into consideration that in a context of increased obesity circu-
lating FFA are usually elevated, thus maintenance of the baseline level
actually reﬂects a decrease compared to the expected phenotype
(Supplemental Figure S4A). In conclusion, these results indicate that
despite the increase in adiposity, which typically correlates with
metabolic dysfunction and peripheral tissue lipid deposition, GPS2
deletion in the adipose tissue appears to have a positive effect on
whole body lipid metabolism with reduced spillover to non-adipose
tissues such as the liver.
Improved lipid storing capacity of the adipose tissue can contribute to
improved systemic insulin sensitivity [3,4,59,60]. Blood glucose levels
after overnight food deprivation were comparable between WT and
GPS2-AKO matched littermate mice (Figure 5F), and glucose tolerance
tests (GTT) were also normal (Figure 5G). However, plasma insulin
levels under the same experimental fasting conditions were signiﬁ-
cantly reduced in GPS2-AKO mice (Figure 5H), consistent with our
previous data that AKT is activated in vitro in basal conditions and
in vivo under food deprivation upon GPS2 deletion/downregulation. To
directly test the insulin sensitivity of GPS2-AKO mice, we injected
matching cohorts of WT and GPS2-AKO littermates with a suboptimal
dose of insulin after a short morning fast. Baseline insulin levels of
GPS2-AKO mice tended to be lower under these experimental condi-
tions as well (Supplemental Figure S4B), and insulin-induced glucose
clearance was greater in GPS2-AKO mice than WT littermates
(Figure 5I), conﬁrming the predicted improvement in insulin sensitivity.
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Figure 5: Uncoupling of adipose tissue inﬂammation, obesity and insulin sensitivity in GPS2-AKO mice under chow diet. (A) RT-qPCR analysis of pro-inﬂammatory genes and
macrophage markers in the WAT. (B) Macrophage inﬁltration in the WAT as measured by FACS analysis with quantiﬁcation of f4/80 and CD11b positive cells. Statistical signiﬁcance
was calculated comparing 3 independent experiments. (C) Plasma adiponectin and leptin levels after an overnight fast, n ¼ 7. (D) Representative H&E staining of parafﬁn-
embedded liver sections imaged at 10 magniﬁcation. (E) Hepatic expression of gluconeogenic and de novo lipogenesis genes by RT-qPCR analysis. (F) Fasting blood
glucose levels in AKO versus WT mice after overnight fast, n ¼ 8. (G) Glucose tolerance test following glucose i.p. injection (1.5 mg/g of body weight) after an overnight fast, n ¼ 4.
(H) Plasma insulin levels in AKO versus WT mice after overnight fast, n ¼ 5e7. Statistical signiﬁcance was calculated comparing 3 independent experiments. (I) Insulin tolerance
test after a 0.5 U/kg body weight insulin i.p. injection in AKO versus WT mice following a 4 h fast, n ¼ 7e8. Results are expressed as meanH SEM. Statistical signiﬁcance was
calculated by two-tailed Student’s t test; *represents p value < 0.05 and **p value < 0.01.
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In conclusion, taken together, our results indicate that enhancing in-
sulin signaling in the adipose tissue, through GPS2 deletion and
modulation of AKT ubiquitination status, has a positive effect on whole
body insulin sensitivity despite the increased adiposity.
4. DISCUSSION
Insulin action is critically required for promoting cell growth, regulating
tissue development, and controlling whole body metabolism through
modulation of glucose homeostasis and lipid metabolism. Its disruption
or reduced functionality leads to the development of insulin resistance, a
hallmark of Type 2 Diabetes and other metabolic disorders. The
signaling mechanisms that mediate the physiological responses to in-
sulin have been thoroughly studied with the identiﬁcation of multiple
transduction pathways, including both positive and negative regulators.
Major players in these pathways are kinases, which are usually counter-
regulated by opposing phosphatases (i.e. PI3K and PTEN). Our work has
further extended this signaling network by revealing the existence of an
additional level of regulation based on the opposing actions of an
ubiquitin conjugating enzyme Ubc13 and its endogenous inhibitor GPS2.
Insulin-mediated ubiquitination of AKT, via Ubc13-mediated synthesis of
K63 ubiquitin chains, is an unexpected, critical step for the activation of
downstream signaling events. Non-proteolytic ubiquitination of AKT had
been previously reported for growth factor-mediated pathways, and a
cancer-associated mutation that affects the ubiquitination of AKT1
(E17K) had been linked to AKT hyperactivation in breast and colon
cancer. In this context, the gain of an additional lysine in the PH domain
was found to promote enhanced AKT ubiquitination, constitutive
recruitment to the membrane, and activation [14,70,71]. Interestingly,
exome sequencing of patients with severe hypoglycemia but unde-
tectable plasma insulin has recently led to the identiﬁcation of a ho-
mologous activating mutation in AKT2 that might be similarly promoting
enhanced ubiquitination. Overexpression of the E17K mutant in 3T3-L1
preadipocytes promoted insulin-independent localization of both AKT
and GLUT4 to the plasma membrane and nuclear export of FoxO1,
indicating constitutive activation of the AKT signaling pathway [72,73].
These observations support our ﬁndings that regulation of AKT activa-
tion by ubiquitination is a conserved feature among the metabolic and
growth signaling pathways mediated by different AKT isoforms. They
also indicate that the non-proteolytic ubiquitination of AKT represents a
key regulatory node for both adipose tissue and systemic homeostasis
and metabolism.
In addition to revealing a role for K63 ubiquitination in the insulin
pathway, our work has identiﬁed GPS2 as an endogenous inhibitor of
this regulatory step. We previously characterized GPS2 as an inhibitor
of Ubc13/TRAF2-6 activity in the context of pro-inﬂammatory pathways
downstream of TNFa and TLR receptors [29]. Here, we conﬁrm that a
signiﬁcant increase in JNK activation in primary adipocytes is observed
upon GPS2 deletion. We also report the novel ﬁnding that GPS2 is a
critical player in the insulin transduction pathway. In particular, our
data reveal that physiological levels of GPS2 in adipocytes are required
for preventing the constitutive ubiquitination of AKT, and therefore the
restriction of its activation, as well as the activation of downstream
signaling events, when insulin levels are low. In accord with these
conclusions, we found that GPS2 deletion in mice adipose tissue re-
sults in constitutive ubiquitination and activation of AKT, leading to
disrupted lipid metabolism and increased adiposity but also to elevated
adiponectin levels. Interestingly, overexpression studies in mice indi-
cate that increasing the level of secreted adiponectin contributes to
mimicking a state of constant feeding and results in improved insulin
sensitivity despite the substantial expansion of the adipose tissue
[1,51,69]. Similarly, deletion of PTEN, a well-known inhibitor of AKT,
promotes sustained insulin signaling and improved insulin sensitivity
despite a signiﬁcant increase in body weight [51]. Our results indicate
that the absence of GPS2 similarly favors the retention of triglycerides
in the adipose tissue, and thus improvement of insulin sensitivity in
mice that become obese when fed a regular laboratory chow diet.
Interestingly, our previous work showed GPS2 playing an important
anti-inﬂammatory role in the regulation of pro-inﬂammatory signaling
pathways. The anti-inﬂammatory role of GPS2 was then conﬁrmed by
macrophage-speciﬁc and B-cell-speciﬁc deletion studies and by GPS2
overexpression in the adipose tissue (both adipocytes and macro-
phages) of DIO obese mice [29,74] (Lentucci et al., under revision). In
contrast, we report here that GPS2 adipo-speciﬁc deletion has a positive
effect on adipocyte insulin signaling and systemic insulin sensitivity in
chow-fed mice, and that, under these conditions, inﬂammation of the
adipose tissue is undetectable in GPS2-AKO mice despite their increase
in body fat. These observations are in agreement with a recent report
that hyperinsulenimia can drive adipose tissue inﬂammation, whereas a
reduction in circulating insulin levels causes a decrease in the
expression of pro-inﬂammatory markers and macrophage expansion in
the adipose tissue [75]. Thus, our ﬁndings reveal that GPS2 plays an
intriguing role at the intersection between inﬂammatory and metabolic
pathways, and suggest that sustained AKT activation through enhanced
ubiquitination is likely to overcome the negative effect that the elevated
levels of P-JNK might have on insulin signaling via IRS1 phosphoryla-
tion. Finally, it is important to note that there are layers to the phenotype
associated with the loss of GPS2 function that might depend on the
genetic background and the experimental conditions. For example,
while the GPS2-AKO mice described here become obese even when fed
a chow diet, similar mice generated by Fan and colleagues were not
obese at baseline and did not appear to gain extra weight upon HFD
feeding [74]. Thus, further studies that explore the interplay between
increased activation of pro-inﬂammatory signaling pathways and
enhanced insulin signaling in GPS2-AKO mice will be critical for a
comprehensive understanding of the crosstalk between these pathways
in condition of diet- or genetic-induced obesity. Interestingly, our results
indicate that the synergistic roles played by GPS2 in the regulation of
JNK activity and insulin signaling are mediated through a conserved
mechanism based on the inhibition of Ubc13 enzymatic activity. This
raises the interesting question of whether the ubiquitination machinery
responsible for the synthesis of non-proteolytic K63 ubiquitin chains
represents a key regulatory node between inﬂammation and lipid
metabolism at the onset of obesity.
Lastly, it is worth noting that there is a large body of work describing
GPS2 as a transcriptional cofactor, involved in mediating both gene
repression, as part of the NCoR/SMRT complex, and activation through
direct interaction with nuclear receptors and other TFs
[31,37,39,41,42,76]. For example, in the adipose tissue, down-
regulation of GPS2 was associated with the derepression of inﬂam-
matory target genes in human obese patients [32] and with the
activation of key enzymes for triglyceride breakdown, HSL and ATGL, in
murine differentiating adipocytes [34]. Here, we have conﬁrmed a
critical role for GPS2 in the regulation of adipocyte triglyceride turnover.
However, the expression of HSL and ATGL was not impaired in GPS2-
null primary adipocytes, indicating that lipolysis is likely suppressed
due to the sustained activation of insulin signaling even under baseline
or fasted conditions, rather than direct transcriptional effects. Thus, our
previous and current ﬁndings, taken together, indicate that while GPS2
is essential for the early development of preadipocytes, its deletion at
later stages does not affect differentiation but GPS2 remains essential
for maintaining metabolic homeostasis in mature adipocytes.
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Intriguingly, increased adiposity and altered lipid mobilization have
been previously reported also in the case of mice lacking a binding
partner of GPS2, the transcriptional corepressor TBLR1. The phenotype
observed upon TBLR1 deletion appears to similarly extend beyond the
transcriptional regulation of HSL and ATGL, with TBLR1 being
described as required for controlling multiple steps of the lipolytic
cascade, including both changes in gene expression and a decrease in
the phosphorylation of HSL and other PKA substrates [77]. This sug-
gests that multiple components of the NCoR/SMRT corepressor
complex might play complementary genomic and non-genomic func-
tions in the coordinated regulation of cell homeostasis.
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